FDA warns of liver damage reports with Sanofi drug

Jan 14, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- Federal health officials are warning doctors and patients that a recently-launched heart drug from Sanofi-Aventis SA has been linked to liver damage in a handful of patients.

The said Friday it has received several reports of with Multaq tablets, including two cases in which patients had to have their livers removed. Both patients were women and roughly 70 years old. They had been taking the drug for 4.5 months and 6 months, respectively.

The FDA approved Multaq in July 2009 to treat atrial flutter and which are that can reduce blood flow and lead to stroke. More than a half-million prescriptions for Multaq have been written since the drug was approved.

In an online notice, the FDA said it would add a new warning about the risk for liver damage to the label of Multaq. The agency said patients should contact their doctor if they experience signs of , including nausea, vomiting and fever. If doctors suspect a toxicity issue they should discontinue use of the drug and test the patient's liver enzymes.

Liver toxicity is among the most common drug-related side effects across a number of medication classes.

Multaq already carries a black box warning, the most severe type, stating the drug can cause severe complications, including death, in people with recent severe and should not be used in those patients. Common side effects of the twice-a-day tablets include fatigue, loss of strength, diarrhea, nausea and vomiting.

Paris-based Sanofi reported $84 million in sales for Multaq in the first-half of 2009.

Leerink Swann analyst Seamus Fernandez said the safety warning is unlikely to hurt U.S. sales of drug, which he estimates at $128 million for 2010 and $521 million by 2016.

Sanofi said in a statement it has already issued a letter about the liver injuries to doctors and other health care professionals who prescribe Multaq. The letter recommends prescribers consider giving liver enzyme tests during the first six months of treatment.

"Sanofi-Aventis will continue to be in communication with the FDA and this issue will be closely reviewed and monitored," the company stated.

Explore further: Analgesics prescribed more heavily to women than to men, study finds

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA warning: some patients cannot process Plavix

Mar 12, 2010

(AP) -- The Food and Drug Administration is adding its strongest warning to the label for Plavix, cautioning that some patients do not respond to the blockbuster blood thinner.

FDA questions safety of Glaxo kidney cancer drug

Oct 01, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

Recommended for you

New sleeping pill poised to hit US markets

8 hours ago

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Global recommendations on child medicine

9 hours ago

Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...

FDA has safety concerns on Merck insomnia drug

May 20, 2013

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

US adviser on board of firm that sold anthrax drug

May 20, 2013

(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while ...

User comments : 0

More news stories

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Encouraging signs for bee biodiversity

Declines in the biodiversity of pollinating insects and wild plants have slowed in recent years, according to a new study. Researchers led by the University of Leeds and the Naturalis Biodiversity Centre in the Netherlands ...

New method for producing clean hydrogen

Duke University engineers have developed a novel method for producing clean hydrogen, which could prove essential to weaning society off of fossil fuels and their environmental implications.